Trevor R Norman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8571460/publications.pdf

Version: 2024-02-01

201 papers

5,066 citations

87723 38 h-index 61 g-index

205 all docs 205 docs citations

205 times ranked 4444 citing authors

#	Article	IF	Citations
1	Human Melatonin Suppression by Light is Intensity Dependent. Journal of Pineal Research, 1989, 6, 149-156.	3.4	389
2	Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatrica Scandinavica, 2007, 116 , 41 - 49 .	2.2	317
3	A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 848-859.	0.8	156
4	Behavioural studies of spatial working memory dysfunction in schizophrenia: A quantitative literature review. Psychiatry Research, 2007, 150, 111-121.	1.7	142
5	Acute increases in night-time plasma melatonin levels following a period of meditation. Biological Psychology, 2000, 53, 69-78.	1.1	116
6	Melatonin Sensitivity to Dim White Light in Affective Disorders. Neuropsychopharmacology, 1999, 21, 408-413.	2.8	106
7	Overnight human plasma melatonin, Cortisol, prolactin, TSH, under conditions of normal sleep, sleep deprivation, and sleep recovery. Journal of Pineal Research, 1996, 20, 7-14.	3.4	96
8	Selective Effects of Acute Serotonin and Catecholamine Depletion on Memory in Healthy Women. Journal of Psychopharmacology, 2004, 18, 32-40.	2.0	92
9	Treatment of Seasonal Affective Disorder with Light: Preliminary Australian Experience. Australian and New Zealand Journal of Psychiatry, 1989, 23, 369-372.	1.3	88
10	Effect of Sodium Valproate on Nocturnal Melatonin Sensitivity to Light in Healthy Volunteers. Neuropsychopharmacology, 2005, 30, 1400-1404.	2.8	82
11	Impairments of Spatial Working Memory and Attention Following Acute Psychosocial Stress. Stress and Health, 2015, 31, 115-123.	1.4	80
12	Neuropsychological study of underweight and "weightâ€recoveredâ€anorexia nervosa compared with bulimia nervosa and normal controls. International Journal of Eating Disorders, 2007, 40, 613-621.	2.1	75
13	Serotonin in Panic Disorder. International Clinical Psychopharmacology, 1989, 4, 1-6.	0.9	71
14	Melatonin Rhythm in Human Plasma Saliva. Journal of Pineal Research, 1987, 4, 177-183.	3.4	70
15	Platelet monoamine oxidase: Low activity in cigarette smokers. Psychiatry Research, 1987, 20, 199-205.	1.7	69
16	Quantal melatonin suppression by exposure to low intensity light in man. Life Sciences, 1989, 45, 327-332.	2.0	69
17	The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins. Psychoneuroendocrinology, 2006, 31, 867-875.	1.3	68
18	Dopamine D1 receptor binding in the striatum of patients with obsessive–compulsive disorder. Journal of Affective Disorders, 2009, 114, 321-326.	2.0	68

#	Article	IF	CITATIONS
19	Breastfeeding and the use of psychotropic medication: a review. Journal of Affective Disorders, 1990, 19, 197-206.	2.0	65
20	Alterations to Plasma Melatonin and Cortisol After Evening Alprazolam Administration in Humans. Chronobiology International, 1993, 10, 205-213.	0.9	63
21	Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers. International Journal of Neuropsychopharmacology, 2005, 8, 255-259.	1.0	61
22	Platelet monoamine oxidase activity and cigarette smoking. Journal of Affective Disorders, 1982, 4, 73-77.	2.0	59
23	Combining pindolol and paroxetine in an animal model of chronic antidepressant action—can early onset of action be detected?. European Journal of Pharmacology, 1998, 352, 23-28.	1.7	57
24	Third-Generation Antidepressants. CNS Drugs, 2001, 15, 941-954.	2.7	57
25	Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans. Biological Psychiatry, 1988, 24, 108-112.	0.7	52
26	Onset of the Effects of the 5-HT1A Antagonist, WAY-100635, Alone, and in Combination With Paroxetine, on Olfactory Bulbectomy and 8-OH-DPAT–Induced Changes in the Rat. Pharmacology Biochemistry and Behavior, 1999, 63, 333-338.	1.3	51
27	Olanzapine excretion in human breast milk: estimation of infant exposure. International Journal of Neuropsychopharmacology, 2002, 5, 243-7.	1.0	51
28	A controlled study of a specific MAO a reversible inhibitor (R011-1163) and amitriptyline in depressive illness. Journal of Affective Disorders, 1985, 8, 29-35.	2.0	45
29	Human melatonin response to light at different times of the night. Psychoneuroendocrinology, 1989, 14, 187-193.	1.3	45
30	The treatment of depression with different formulations of venlafaxine: a comparative analysis. Human Psychopharmacology, 2004, 19, 9-16.	0.7	45
31	Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. Biomedical Applications, 2000, 748, 439-443.	1.7	44
32	In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. Human Psychopharmacology, 2001, 16, 541-544.	0.7	44
33	Plasma Melatonin Concentrations in Depression. Australian and New Zealand Journal of Psychiatry, 1986, 20, 381-383.	1.3	42
34	The emerging role of pharmacogenetics: implications for clinical psychiatry. Australian and New Zealand Journal of Psychiatry, 2004, 38, 483-489.	1.3	42
35	Platelet serotonin uptake in panic disorder. Journal of Affective Disorders, 1986, 11, 69-72.	2.0	41
36	Serotonergic and Dopaminergic Systems in Anorexia Nervosa: A Role for Atypical Antipsychotics?. Australian and New Zealand Journal of Psychiatry, 2005, 39, 146-153.	1.3	40

#	Article	IF	Citations
37	Stability of cognitive impairment in chronic schizophrenia over brief and intermediate reâ€test intervals. Human Psychopharmacology, 2009, 24, 113-121.	0.7	40
38	Agomelatine for depression: expanding the horizons?. Expert Opinion on Pharmacotherapy, 2019, 20, 647-656.	0.9	40
39	The biological basis of anxiety. Journal of Affective Disorders, 1985, 9, 271-284.	2.0	38
40	Low platelet monoamine oxidase and sensation seeking in males: an established relationship?. Acta Psychiatrica Scandinavica, 1987, 75, 86-90.	2.2	37
41	The Evaluation of Depression in Inpatients with HIV Disease. Australian and New Zealand Journal of Psychiatry, 1999, 33, 344-352.	1.3	36
42	Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers. Human Psychopharmacology, 2003, 18, 619-625.	0.7	36
43	Analysis of tricyclic antidepressant drugs in plasma and serum by chromatographic techniques. Biomedical Applications, 1985, 340, 173-197.	1.7	34
44	Spatial working memory and problem solving in schizophrenia: The effect of symptom stabilization with atypical antipsychotic medication. Psychiatry Research, 2008, 160, 316-326.	1.7	34
45	Cigarette smoking and plasma nortriptyline levels. Clinical Pharmacology and Therapeutics, 1977, 21, 453-456.	2.3	33
46	The effect of gender on the melatonin suppression by light: a dose response relationship. Journal of Neural Transmission, 2000, 107, 271-279.	1.4	32
47	Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5â€HT _{1A} receptor agonist. Human Psychopharmacology, 2009, 24, 437-446.	0.7	32
48	Dopamine D1 receptor binding in the anterior cingulate cortex of patients with obsessive–compulsive disorder. Psychiatry Research - Neuroimaging, 2010, 183, 85-88.	0.9	31
49	The effect of venlafaxine treatment on the behavioural and neurochemical changes in the olfactory bulbectomised rat. Psychopharmacology, 1998, 136, 394-401.	1.5	30
50	Modulation of plasma melatonin concentrations by changes in posture. Journal of Pineal Research, 1998, 24, 219-223.	3.4	29
51	An open-label study of quetiapine in anorexia nervosa. Human Psychopharmacology, 2007, 22, 223-230.	0.7	29
52	Abnormal dose-response melatonin suppression by light in bipolar type I patients compared with healthy adult subjects. Acta Neuropsychiatrica, 2009, 21, 246-255.	1.0	29
53	Pharmacological Treatment of Panic Disorder. International Clinical Psychopharmacology, 1986, 1, 3-16.	0.9	27
54	The effect of dim light on suppression of nocturnal melatonin in healthy women and men. Journal of Neural Transmission, 1997, 104, 643-648.	1.4	27

#	Article	lF	CITATIONS
55	Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Human Psychopharmacology, 2000, 15, 161-264.	0.7	27
56	Pindolol Augmentation of Antidepressants: A Review and Rationale. Australian and New Zealand Journal of Psychiatry, 2000, 34, 71-79.	1.3	27
57	Melatonin, cortisol and prolactin response to acute nocturnal light exposure in healthy volunteers. Psychoneuroendocrinology, 1992, 17, 243-248.	1.3	26
58	New Formulations of Existing Antidepressants. CNS Drugs, 2004, 18, 505-520.	2.7	26
59	Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: The effect of smoking. European Journal of Clinical Pharmacology, 1981, 21, 229-233.	0.8	24
60	Prolactin response to dl-fenfluramine in panic disorder. Psychoneuroendocrinology, 1993, 18, 337-342.	1.3	24
61	A Multicentre Double Blind Trial of Fluoxetine versus Amitriptyline in the Treatment of Depressive Illness. Australian and New Zealand Journal of Psychiatry, 1993, 27, 49-55.	1.3	24
62	The effect of atenolol, a p!-adrenergic antagonist, on nocturnal plasma melatonin secretion: Evidence for a dose-response relationship in humans. Journal of Pineal Research, 1997, 23, 131-135.	3.4	24
63	A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients. International Clinical Psychopharmacology, 2006, 21, 87-92.	0.9	24
64	Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT2c antagonist, S32006. European Journal of Pharmacology, 2012, 674, 27-32.	1.7	24
65	Neurochemical effects of the enantiomers of mirtazapine in normal rats. European Journal of Pharmacology, 1998, 356, 121-126.	1.7	23
66	Metabolism and pharmacokinetics of dothiepin British Journal of Clinical Pharmacology, 1981, 12, 405-409.	1.1	22
67	Negative symptoms, depression and parkinsonian symptoms in chronic, hospitalised schizophrenic patients. Journal of Affective Disorders, 1998, 48, 163-169.	2.0	22
68	Determination of nefazodone and its pharmacologically active metabolites in human blood plasma and breast milk by high-performance liquid chromatography. Biomedical Applications, 1999, 730, 249-255.	1.7	22
69	Antidepressants and Breast-Feeding. Paediatric Drugs, 2000, 2, 183-192.	1.3	22
70	Effects of serotonin and catecholamine depletion on interleukin-6 activation and mood in human volunteers. Human Psychopharmacology, 2002, 17, 293-297.	0.7	20
71	Plasma and breast milk concentrations of dothiepin and northiaden in lactating women. Human Psychopharmacology, 1993, 8, 29-33.	0.7	19
72	Long-term drug treatment of panic disorder. Journal of Psychiatric Research, 1993, 27, 111-125.	1.5	19

#	Article	IF	Citations
73	Fast-Acting Antidepressants. CNS Drugs, 1994, 2, 120-131.	2.7	19
74	3. Assessment of anxiety and depression in primary care. Medical Journal of Australia, 1997, 167, 328-333.	0.8	19
75	Discontinuation Syndromes with Selective Serotonin Reuptake Inhibitors. CNS Drugs, 1999, 12, 171-177.	2.7	19
76	Brain serotonin depletion by lesions of the median raphe nucleus enhances the psychotomimetic action of phencyclidine, but not dizocilpine (MK-801), in rats. Brain Research, 2005, 1049, 217-226.	1.1	19
77	Quetiapine augmentation in depressed patients with partial response to antidepressants. Human Psychopharmacology, 2008, 23, 653-660.	0.7	19
78	A pharmacokinetic study of mianserin. European Journal of Clinical Pharmacology, 1982, 21, 517-520.	0.8	18
79	Measurement of moclobamide, a new monoamine oxidase inhibitor, by gas chromatography with nitrogen-selective detection. Biomedical Applications, 1983, 278, 429-433.	1.7	18
80	The pineal hormone melatonin in panic disorder. Journal of Affective Disorders, 1987, 12, 203-206.	2.0	18
81	Platelet serotonin uptake and 3H-imipramine binding in panic disorder. Journal of Affective Disorders, 1989, 17, 77-81.	2.0	18
82	Emerging treatments for major depression. Expert Review of Neurotherapeutics, 2007, 7, 203-213.	1.4	17
83	Treatment of Seasonal Affective Disorder with Light: Preliminary Australian Experience. Australian and New Zealand Journal of Psychiatry, 1989, 23, 369-372.	1.3	17
84	Serotonergic function in panic disorder: Endocrine responses to d-Fenfluramine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1994, 18, 329-337.	2.5	16
85	Treatment of Anxiety During Pregnancy. Drug Safety, 1999, 20, 171-186.	1.4	16
86	Blunted growth hormone response to clonidine in post-traumatic stress disorder. Psychoneuroendocrinology, 2004, 29, 269-278.	1.3	16
87	An investigation of the effect of tacrine and physostigmine on spatial working memory deficits in the olfactory bulbectomised rat. Behavioural Brain Research, 2004, 153, 481-486.	1.2	16
88	The Impact of a Changed Environment on Arousal Levels of Patients in a Secure Extended Rehabilitation Facility. Australasian Psychiatry, 2009, 17, 207-211.	0.4	16
89	New Pharmacological Approaches to the Management of Depression: From Theory to Clinical Practice. Australian and New Zealand Journal of Psychiatry, 1992, 26, 73-81.	1.3	15
90	Aggressive behaviour and platelet 3H-paroxetine binding in schizophrenia. Schizophrenia Research, 1997, 23, 61-67.	1.1	15

#	Article	IF	CITATIONS
91	PHARMACOKINETICS AND PLASMA LEVELS OF ANTIDEPRESSANTS IN THE ELDERLY. Medical Journal of Australia, 1979, 1, 273-274.	0.8	15
92	Simultaneous measurement of dothiepin and its major metabolites in plasma and whole blood by gas chromatography—mass fragmentography. Biomedical Applications, 1981, 222, 399-408.	1.7	14
93	Platelet 3H-rauwolscine binding in patients with panic attacks. Psychiatry Research, 1987, 22, 43-48.	1.7	14
94	Fenfluramine Augmentation of Clomipramine Treatment of Obsessive Compulsive Disorder. Australian and New Zealand Journal of Psychiatry, 1991, 25, 412-414.	1.3	14
95	Sertraline Analysis in the Plasma of Breast-Fed Infants. Australian and New Zealand Journal of Psychiatry, 2001, 35, 545-546.	1.3	14
96	Psychotherapeutic Drugs, 1980, 20, 485-493.	4.9	13
97	Determination of tiapride in plasma by high-performance liquid chromatography. Biomedical Applications, 1986, 375, 197-201.	1.7	13
98	A Risk-Benefit Assessment of Moclobemide in the Treatment of Depressive Disorders. Drug Safety, 1995, 12, 46-54.	1.4	13
99	Successful treatment of serotonin syndrome with chlorpromazine. Medical Journal of Australia, 1996, 165, 345-346.	0.8	13
100	Platelet paroxetine binding in post-traumatic stress disorder. Psychiatry Research, 1998, 77, 1-7.	1.7	13
101	Continuation treatment of major depressive disorder: is there a case for duloxetine?. Drug Design, Development and Therapy, 2010, 4, 19.	2.0	13
102	Melatonin sensitivity to light in monozygotic twins discordant for bipolar I disorder. Australian and New Zealand Journal of Psychiatry, 2005, 39, 947.	1.3	13
103	Determination of therapeutic levels of butriptyline in plasma by gas-liquid chromatography. Journal of Chromatography A, 1977, 134, 524-528.	1.8	12
104	The pharmacokinetics of mianserin in elderly depressed patients. Psychiatry Research, 1983, 8, 281-287.	1.7	12
105	Platelet serotonin uptake in panic disorder patients: A replication study. Psychiatry Research, 1989, 30, 63-68.	1.7	12
106	Blunted prolactin response to ?-fenfluramine in post-stroke major depression. Journal of Affective Disorders, 2003, 76, 273-278.	2.0	12
107	5-HT2A Agonists: A Novel Therapy for Functional Neurological Disorders?. International Journal of Neuropsychopharmacology, 2017, 20, 422-427.	1.0	12
108	Platelet [3H]paroxetine binding in panic disorder. Journal of Affective Disorders, 1995, 33, 117-122.	2.0	11

#	Article	IF	Citations
109	Nocturnal plasma melatonin concentrations in healthy volunteers: Effect of single doses of d-fenfluramine, paroxetine, and ipsapirone. Journal of Pineal Research, 1996, 21, 55-58.	3.4	11
110	5. Benzodiazepines in anxiety disorders: managing therapeutics and dependence. Medical Journal of Australia, 1997, 167, 490-495.	0.8	11
111	The effect of age and pre-light melatonin concentration on the melatonin sensitivity to dim light. International Clinical Psychopharmacology, 1999, 14, 189-192.	0.9	11
112	Prolactin response to d-fenfluramine in combat-related post-traumatic stress disorder. International Journal of Neuropsychopharmacology, 2004, 7, 291-298.	1.0	11
113	Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists. Behavioural Brain Research, 2005, 161, 286-290.	1.2	11
114	Prospects for the Treatment of Depression. Australian and New Zealand Journal of Psychiatry, 2006, 40, 394-401.	1.3	11
115	Duloxetine in the treatment of generalized anxiety disorder. Neuropsychiatric Disease and Treatment, 2009, 4, 1169.	1.0	11
116	Psychosis after withdrawal of steroid therapy. Medical Journal of Australia, 1983, 2, 350-351.	0.8	11
117	Viloxazine plasma concentrations and clinical response. Journal of Affective Disorders, 1980, 2, 157-164.	2.0	10
118	Antidepressant therapy: benefits and risks in perspective. Acta Psychiatrica Scandinavica, 1985, 72, 43-47.	2.2	10
119	Platelet Serotonin Uptake in Panic Disorder: Comparison with Normal Controls and the Effect of Treatment. Australian and New Zealand Journal of Psychiatry, 1988, 22, 390-395.	1.3	10
120	A Case of Moclobemide Overdose. International Clinical Psychopharmacology, 1988, 3, 325-326.	0.9	10
121	High-affinity platelet [3H]LSD binding is decreased in panic disorder. Journal of Affective Disorders, 1990, 19, 119-123.	2.0	10
122	Evidence for 5-HT1A receptor control of pineal melatonin concentrations in the rat. European Neuropsychopharmacology, 1998, 8, 183-186.	0.3	10
123	Effect of the menstrual cycle stage on the melatonin suppression by dim white light. Psychoneuroendocrinology, 1999, 24, 193-200.	1.3	10
124	Nefazodone in the Breast Milk of Nursing Mothers: A Report of Two Patients. Journal of Clinical Psychopharmacology, 2000, 20, 717-718.	0.7	10
125	A CONTROLLED COMPARATIVE TRIAL OF CLORAZEPATE (TRANXENE) AND DIAZEPAM (VALIUM) FOR ANXIETY. Medical Journal of Australia, 1977, 2, 525-528.	0.8	9
126	Pharmacokinetic aspects of antidepressant treatment in the elderly. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1993, 17, 329-344.	2.5	9

#	Article	IF	CITATIONS
127	Olanzapine in Anorexia Nervosa. Australian and New Zealand Journal of Psychiatry, 2003, 37, 494-494.	1.3	9
128	Anxiety and the Benzodiazepine Receptor. Progress in Brain Research, 1986, 65, 73-90.	0.9	8
129	Plasma immunoreactive \hat{l}^2 -endorphin in dexamethasone suppressors and non-suppressors of cortisol. Journal of Affective Disorders, 1987, 12, 233-239.	2.0	8
130	The effect of stress on melatonin and serotonin in rat brain. Stress and Health, 1989, 5, 5-8.	0.7	8
131	A Short Term Open Clinical Trial of Clobazam in the Treatment of Patients with Panic Attacks. International Clinical Psychopharmacology, 1989, 4, 285-294.	0.9	8
132	Differential Diagnosis and Drug Treatment of Panic Disorder, Anxiety and Depression. CNS Drugs, 1994, 1, 119-131.	2.7	8
133	Plasma and human milk concentrations of moclobemide in nursing mothers. Human Psychopharmacology, 1998, 13, 579-582.	0.7	8
134	The effect of single oral doses of zopiclone on nocturnal melatonin secretion in healthy male volunteers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2001, 25, 825-833.	2.5	8
135	The Emerging Role of Pharmacogenetics: Implications for Clinical Psychiatry. Australian and New Zealand Journal of Psychiatry, 2004, 38, 483-489.	1.3	8
136	A NEW ANTIDEPRESSANT BUTRIPTYLINE: PLASMA LEVELS AND CLINICAL RESPONSE. Medical Journal of Australia, 1977, 2, 604-606.	0.8	8
137	Plasma Nomifensine Concentration. International Pharmacopsychiatry, 1980, 15, 325-333.	0.4	7
138	Zimelidine: A placebo-controlled trial in depression. Psychiatry Research, 1983, 8, 95-103.	1.7	7
139	Plasma concentrations of benzodiazepines — A review of clinical findings and implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1984, 8, 115-126.	2.5	7
140	PLATELET MONOAMINE OXIDASE ACTIVITY IN PATIENTS WITH HUNTINGTON'S DISEASE. Clinical and Experimental Pharmacology and Physiology, 1987, 14, 547-550.	0.9	7
141	Pharmacotherapy of Panic Disorder. International Review of Psychiatry, 1990, 2, 399-409.	1.4	7
142	Melatonin sensitivity to dim white light in different seasons. Human Psychopharmacology, 1999, 14, 53-58.	0.7	7
143	An investigation of the effect of immediate and extended release venlafaxine on nocturnal melatonin and cortisol release in healthy adult volunteers. Human Psychopharmacology, 2008, 23, 129-137.	0.7	7
144	One-Year Treatment Continuation in Patients Switched to Paliperidone Palmitate. Journal of Clinical Psychiatry, 2014, 75, 1267-1269.	1.1	7

#	Article	IF	Citations
145	Melatonin in panic disorder. Biological Psychiatry, 1986, 21, 1438-1439.	0.7	6
146	A kinetic analysis of platelet monoamine oxidase activity in patients with panic attacks. Journal of Affective Disorders, 1988, 15, 127-130.	2.0	6
147	Subsensitive melatonin suppression by dim white light: possible biological marker of panic disorder. International Journal of Neuropsychopharmacology, 1998, 1, 115-120.	1.0	6
148	The effect of age and pre-light melatonin concentration on the melatonin sensitivity to dim light. International Clinical Psychopharmacology, 1999, 14, 189-192.	0.9	6
149	The neurobiology of benzodiazepine receptors in panic disorder and postâ€traumatic stress disorder. Stress and Health, 2008, 24, 13-21.	1.4	6
150	Ethnic differences in psychotropic drug response and pharmacokinetics., 2008,, 38-61.		6
151	Desvenlafaxine in the treatment of major depression: an updated overview. Expert Opinion on Pharmacotherapy, 2021, 22, 1087-1097.	0.9	6
152	Maprotiline in affective illness. Journal of Affective Disorders, 1983, 5, 147-154.	2.0	5
153	ANTIDEPRESSANTS: CLINICAL ASPECTS. Stress and Health, 1997, 13, 167-172.	0.7	5
154	Melatonin: hormone of the night. Acta Neuropsychiatrica, 2009, 21, 263-265.	1.0	5
155	Doxepin Plasma Levels and Anxiolytic Response. International Pharmacopsychiatry, 1980, 15, 247-252.	0.4	4
156	Plasma Prolactin and Fluphenazine Concentrations in Patients receiving Fluphenazine Decanoate: Stability over Injection Intervals. International Clinical Psychopharmacology, 1987, 2, 299-305.	0.9	4
157	Pharmacokinetic and Pharmacodynamic Effects of a Single Nocturnal Dose of Alprazolam. International Clinical Psychopharmacology, 1990, 5, 111-118.	0.9	4
158	Brain monoamines and early visual information-processing speed. International Journal of Neuropsychopharmacology, 2002, 5, 295-300.	1.0	4
159	Combination Antidepressants are not yet Proven Therapy in the Treatment of Depression. Australasian Psychiatry, 2007, 15, 248-249.	0.4	4
160	Dysfunctional Circadian Rhythms and Mood Disorders: Opportunities for Novel Therapeutic Approaches. Modern Problems of Pharmacopsychiatry, 2010, , 32-52.	2.5	4
161	The effect of agomelatine on 5HT2C receptors in humans: a clinically relevant mechanism?. Psychopharmacology, 2012, 221, 177-178.	1.5	4
162	Liver Impairment Associated with Nomifensine. Australian and New Zealand Journal of Psychiatry, 1983, 17, 288-289.	1.3	3

#	Article	IF	CITATIONS
163	A Portable Light Source for Bright Light Treatment. Sleep, 1990, 13, 272-275.	0.6	3
164	Suicide, violent behaviour and fluoxetine. Medical Journal of Australia, 1994, 161, 404-405.	0.8	3
165	Contemporary Therapies for Depression in Older People. Journal of Pharmacy Practice and Research, 2010, 40, 58-64.	0.5	3
166	Agomelatine, melatonin and depressive disorder. Expert Opinion on Investigational Drugs, 2013, 22, 407-410.	1.9	3
167	An open label trial of venlafaxine in war veterans with chronic post traumatic stress disorder. Australian and New Zealand Journal of Psychiatry, 2000, 34, A31-A31.	1.3	3
168	Who bears the costs of antidepressants in Australia?. Medical Journal of Australia, 1995, 162, 162-162.	0.8	3
169	Treatment of Seasonal Affective Disorder with Light: Preliminary Australian Experience. Australian and New Zealand Journal of Psychiatry, 1989, 23, 369-372.	1.3	2
170	Buspirone and Fluoxetine in the Treatment of OCD. Australian and New Zealand Journal of Psychiatry, 1992, 26, 684-686.	1.3	2
171	Stress and isatin: Effects on the serotonergic system. Stress and Health, 1992, 8, 141-145.	0.7	2
172	Platelet [3H]-paroxetine binding in obsessive-compulsive disorder. Human Psychopharmacology, 1995, 10, 141-146.	0.7	2
173	Stress induced animal models of depression. Stress and Health, 2000, 16, 195-197.	0.7	2
174	Agomelatine, Melatonin and Depression. , 2016, , 229-247.		2
175	Diagnostic agreement and concordance between consultation-liaison psychiatry and non-psychiatric (medical and surgical) doctors: changes within junior doctor's terms. Australasian Psychiatry, 2022, 30, 60-63.	0.4	2
176	Plasma fluphenazine concentrations in outpatients receiving fluphenazine decanoate (Modecate). Human Psychopharmacology, 1986, 1, 89-92.	0.7	1
177	Urinary Tribulin Output in Patients with Panic Attacks. British Journal of Psychiatry, 1988, 152, 295-296.	1.7	1
178	Long-term management of depressive disorders. Current Therapeutic Research, 1993, 54, 832-837.	0.5	1
179	The Test Re-Test Reliability of the Melatonin Suppression by White Light. Biological Rhythm Research, 1999, 30, 467-475.	0.4	1
180	Mechanism of action of mirtazapine: dual action or dual effect?. Australian and New Zealand Journal of Psychiatry, 2004, 38, 267-269.	1.3	1

#	Article	IF	Citations
181	Pharmacotherapy for Mood and Anxiety Disorders. Mental Health and Illness Worldwide, 2017, , 427-453.	0.1	1
182	Presence of olanzapine in breast milk. Australian and New Zealand Journal of Psychiatry, 2000, 34, A16-A16.	1.3	1
183	Fluoxetine — Delayed halfâ€life and an Adverse Event. Medical Journal of Australia, 1993, 158, 722-723.	0.8	1
184	Monitoring and Interpretation of Antidepressant Plasma Concentrations. Australian and New Zealand Journal of Psychiatry, 1982, 16, 74-78.	1.3	0
185	Platelet monoamine uptake in depression ? primary or secondary phenomenon?. Human Psychopharmacology, 1987, 2, 47-47.	0.7	0
186	Platelet serotonin response to treatment in geriatric depression. Biological Psychiatry, 1989, 26, 434-436.	0.7	0
187	Platelet MAO and 5–HT uptake in agoraphobics. British Journal of Psychiatry, 1990, 156, 592-593.	1.7	0
188	Guest Editorial: International Society for the Investigation of Stress (ISIS). Stress and Health, 2002, 18, 59-60.	1.4	0
189	Mechanism of Action of Mirtazapine: Dual Action or Dual Effect?. Australian and New Zealand Journal of Psychiatry, 2004, 38, 267-269.	1.3	0
190	Fifth World Congress on Stress, London, 18–19 June 2004. Stress and Health, 2004, 20, 173-174.	1.4	0
191	Human Embryonic Stem Cells: A Resource for In Vitro Neuroscience Research?. Neuropsychopharmacology, 2006, 31, 2571-2572.	2.8	0
192	How does your garden grow—therapeutic principles from herbal remedies?. Stress and Health, 2008, 24, 1-2.	1.4	0
193	Duloxetine in the acute and continuation treatment of major depressive disorder. Expert Review of Neurotherapeutics, 2011, 11, 1525-1539.	1.4	0
194	The Decline and Fall of the Psychopharmacology Empire?. Australian and New Zealand Journal of Psychiatry, 2011, 45, 1005-1005.	1.3	0
195	Problematic medical marijuana, but not all cannabinoids?. Australian and New Zealand Journal of Psychiatry, 2018, 52, 95-95.	1.3	0
196	Agomelatine: Profile and applications to depression. , 2021, , 301-308.		0
197	A positron emission tomography study of benzodiazepine receptors in post-traumatic stress disorder. Australian and New Zealand Journal of Psychiatry, 2000, 34, A21-A21.	1.3	0
198	Mechanisms underlying the speed of onset of antidepressant response. , 2001, , 47-61.		0

#	Article	IF	CITATIONS
199	Antidepressant Drug Measurement: Review of Methods for Clinical Application. , 1989, , 605-610.		O
200	Pharmacotherapy for Mood and Anxiety Disorders. Mental Health and Illness Worldwide, 2016, , 1-27.	0.1	0
201	Clinical evaluation of the cardiac effects of new psychotropic drugs. , 1983, , 83-98.		O